Evidence map›Paper›PMID 41324783›Full record

ReviewCurrent cardiology reports2025

Mavacamten in the Treatment of Obstructive Hypertrophic Cardiomyopathy: from Pathophysiology To Real World Data.

Giorgia Panichella, Manuel Garofalo, Maddalena Ragagnin, Angela Ilaria Fanizzi, Mattia Zampieri, Annamaria Del Franco, Francesco Cappelli, Maurizio Pieroni, Iacopo Olivotto

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current cardiology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Giorgia PanichellaDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy. giorgia.panichella@gmail.com.
Manuel GarofaloDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Maddalena RagagninDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Angela Ilaria FanizziDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Mattia ZampieriPediatric Cardiology, Meyer Children's Hospital, Florence, Italy.
Annamaria Del FrancoCardiomyopathy Unit, Careggi University Hospital, Largo Brambilla, 3 , Florence , 50134 Firenze, Italy.
Francesco CappelliDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Maurizio PieroniDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Iacopo OlivottoDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis review aims to provide a comprehensive overview of mavacamten in the management of obstructive hypertrophic cardiomyopathy (oHCM), from its molecular mechanism of action to clinical trial outcomes and real-world application. It explores the efficacy, safety, and practical considerations of mavacamten use, while highlighting evolving indications and future directions. RECENT

findingsRandomized trials have shown that mavacamten significantly reduces left ventricular outflow tract gradients, improves symptoms and exercise capacity, and induces structural reverse remodeling with a favorable safety profile. Real-world data confirm these benefits in broader patient populations. Pharmacogenetic variability, titration protocols, and cost-effectiveness analyses have further refined its clinical use. Mavacamten represents a paradigm shift in oHCM treatment by targeting disease at its sarcomeric origin. Its integration into routine care is expanding, supported by real-world evidence. Ongoing studies will clarify its role in non-obstructive HCM, heart failure with preserved ejection fraction, pediatric populations, and early-stage disease.

Indexed as

Cardiomyopathy, HypertrophicUracilBenzylaminesHumansRandomized Controlled Trials as TopicTreatment OutcomeVentricular RemodelingBenzylaminesMYK-461UracilCardiac myosin inhibitorsCost-effectivenessGenotype-guided therapyLVOT obstructionReverse remodelingSymptom burden

Identifiers

PMID41324783
PMCPMC12669318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.